Latest Insider Transactions at Icu Medical Inc (ICUI)
This section provides a real-time view of insider transactions for Icu Medical Inc (ICUI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ICU MEDICAL INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ICU MEDICAL INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 01
2024
|
Vivek Jain Chairman and CEO |
SELL
Open market or private sale
|
Direct |
12,000
-2.67%
|
$2,064,000
$172.26 P/Share
|
|
Nov 01
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+9.33%
|
$1,056,000
$88.76 P/Share
|
|
Oct 01
2024
|
Vivek Jain Chairman and CEO |
SELL
Open market or private sale
|
Direct |
12,000
-2.67%
|
$2,136,000
$178.91 P/Share
|
|
Oct 01
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+9.33%
|
$1,056,000
$88.76 P/Share
|
|
Sep 03
2024
|
Vivek Jain Chairman and CEO |
SELL
Open market or private sale
|
Direct |
12,000
-3.68%
|
$1,956,000
$163.45 P/Share
|
|
Sep 03
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+3.55%
|
$1,056,000
$88.76 P/Share
|
|
Aug 30
2024
|
Daniel Woolson VP, GM-Infusion Capital |
SELL
Open market or private sale
|
Direct |
2,502
-16.03%
|
$407,826
$163.22 P/Share
|
|
Aug 16
2024
|
Vivek Jain Chairman and CEO |
SELL
Open market or private sale
|
Direct |
12,000
-10.29%
|
$1,872,000
$156.04 P/Share
|
|
Aug 16
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+9.33%
|
$1,056,000
$88.76 P/Share
|
|
Aug 08
2024
|
Virginia Ruth Sanzone VP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,050
-31.38%
|
$295,200
$144.11 P/Share
|
|
May 30
2024
|
Christian B. Voigtlander Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,539
-91.9%
|
$1,304,056
$104.17 P/Share
|
|
May 16
2024
|
Elisha W Finney |
SELL
Open market or private sale
|
Direct |
300
-12.35%
|
$31,200
$104.95 P/Share
|
|
May 15
2024
|
David F Hoffmeister |
BUY
Exercise of conversion of derivative security
|
Direct |
948
+23.85%
|
-
|
|
May 15
2024
|
Donald Abbey |
BUY
Exercise of conversion of derivative security
|
Direct |
948
+23.85%
|
-
|
|
May 15
2024
|
Kolleen T Kennedy |
BUY
Exercise of conversion of derivative security
|
Direct |
948
+37.77%
|
-
|
|
May 15
2024
|
Elisha W Finney |
BUY
Exercise of conversion of derivative security
|
Direct |
948
+28.07%
|
-
|
|
May 15
2024
|
Laurie Hernandez Director |
BUY
Exercise of conversion of derivative security
|
Direct |
948
+33.46%
|
-
|
|
May 15
2024
|
David C. Greenberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
948
+15.84%
|
-
|
|
May 10
2024
|
Ben Sousa Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,000
-60.26%
|
$210,000
$105.55 P/Share
|
|
Mar 15
2024
|
Christian B. Voigtlander Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,780
-12.43%
|
$174,440
$98.08 P/Share
|
|
Mar 15
2024
|
Christian B. Voigtlander Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,247
+18.48%
|
-
|
|
Mar 15
2024
|
Ben Sousa Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
463
-12.24%
|
$45,374
$98.08 P/Share
|
|
Mar 15
2024
|
Ben Sousa Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,299
+25.57%
|
-
|
|
Mar 15
2024
|
Daniel Woolson VP, GM-Infusion Capital |
SELL
Payment of exercise price or tax liability
|
Direct |
1,294
-7.66%
|
$126,812
$98.08 P/Share
|
|
Mar 15
2024
|
Daniel Woolson VP, GM-Infusion Capital |
BUY
Exercise of conversion of derivative security
|
Direct |
2,923
+14.74%
|
-
|
|
Mar 15
2024
|
Virginia Ruth Sanzone VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
890
-11.99%
|
$87,220
$98.08 P/Share
|
|
Mar 15
2024
|
Virginia Ruth Sanzone VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,624
+17.95%
|
-
|
|
Mar 15
2024
|
Brian Michael Bonnell Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,780
-6.66%
|
$174,440
$98.08 P/Share
|
|
Mar 15
2024
|
Brian Michael Bonnell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,247
+10.83%
|
-
|
|
Mar 15
2024
|
Vivek Jain Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,671
-2.49%
|
$261,758
$98.08 P/Share
|
|
Mar 15
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,871
+4.34%
|
-
|
|
Mar 15
2024
|
Daniel Woolson VP, GM-Infusion Capital |
SELL
Open market or private sale
|
Direct |
791
-5.36%
|
$77,518
$98.27 P/Share
|
|
Mar 14
2024
|
George A Lopez Director |
SELL
Open market or private sale
|
Indirect |
7,978
-0.9%
|
$805,778
$101.87 P/Share
|
|
Mar 12
2024
|
George A Lopez Director |
SELL
Open market or private sale
|
Direct |
1,522
-0.48%
|
$153,722
$101.51 P/Share
|
|
Mar 11
2024
|
George A Lopez Director |
SELL
Open market or private sale
|
Direct |
1,890
-0.59%
|
$196,560
$104.22 P/Share
|
|
Mar 08
2024
|
Daniel Woolson VP, GM-Infusion Capital |
SELL
Payment of exercise price or tax liability
|
Direct |
894
-5.71%
|
$92,976
$104.52 P/Share
|
|
Mar 08
2024
|
Daniel Woolson VP, GM-Infusion Capital |
BUY
Exercise of conversion of derivative security
|
Direct |
2,020
+11.42%
|
-
|
|
Mar 08
2024
|
Christian B. Voigtlander Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,210
-20.0%
|
$541,840
$104.52 P/Share
|
|
Mar 08
2024
|
Christian B. Voigtlander Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,499
+26.16%
|
-
|
|
Mar 08
2024
|
Ben Sousa Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
240
-8.81%
|
$24,960
$104.52 P/Share
|
|
Mar 08
2024
|
Ben Sousa Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
674
+19.84%
|
-
|
|
Mar 08
2024
|
Vivek Jain Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,953
-2.83%
|
$619,112
$104.52 P/Share
|
|
Mar 08
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,856
+4.84%
|
-
|
|
Mar 08
2024
|
Brian Michael Bonnell Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,210
-10.1%
|
$541,840
$104.52 P/Share
|
|
Mar 08
2024
|
Brian Michael Bonnell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,499
+15.16%
|
-
|
|
Mar 08
2024
|
George A Lopez Director |
SELL
Open market or private sale
|
Direct |
15,372
-4.59%
|
$1,614,060
$105.94 P/Share
|
|
Mar 08
2024
|
Virginia Ruth Sanzone VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,246
-17.69%
|
$129,584
$104.52 P/Share
|
|
Mar 08
2024
|
Virginia Ruth Sanzone VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,273
+24.4%
|
-
|
|
Mar 08
2024
|
Virginia Ruth Sanzone VP, General Counsel |
SELL
Open market or private sale
|
Direct |
3,300
-40.89%
|
$343,200
$104.57 P/Share
|
|
Mar 07
2024
|
Daniel Woolson VP, GM-Infusion Capital |
SELL
Payment of exercise price or tax liability
|
Direct |
2,990
-9.87%
|
$313,950
$105.39 P/Share
|